## Novel Drug Approvals for 2024

1. **Iqirvo**: Approved on June 10, 2024, Iqirvo, containing the active ingredient elafibranor, is indicated for the treatment of primary biliary cholangitis. It is to be used in combination with ursodeoxycholic acid.

2. **Rytelo**: Approved on June 6, 2024, Rytelo, which contains imetelstat, is approved for the treatment of low- to intermediate-1 risk myelodysplastic syndromes.

3. **Imdelltra**: On May 16, 2024, Imdelltra was approved. This drug, with the active ingredient tarlatamab-dlle, is used for treating extensive stage small cell lung cancer.

4. **Xolremdi**: Approved on April 26, 2024, Xolremdi contains mavorixafor and is indicated for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections, and myelokathexis).

5. **Ojemda**: Ojemda, with the active ingredient tovorafenib, was approved on April 23, 2024, for the treatment of relapsed or refractory pediatric low-grade glioma.

6. **Anktiva**: Approved on April 22, 2024, Anktiva contains nogapendekin alfa inbakicept-pmln and is used for treating bladder cancer.

7. **Lumisight**: On April 17, 2024, Lumisight was approved. This drug, with the active ingredient pegulicianine, is used as an optical imaging agent for the detection of cancerous tissue.

8. **Zevtera**: Approved on April 3, 2024, Zevtera contains ceftobiprole medocaril sodium and is used for treating certain bloodstream infections, bacterial skin and associated tissue infections, and community-acquired bacterial pneumonia.

9. **Voydeya**: Voydeya, which contains danicopan, was approved on March 29, 2024. It is indicated for the treatment of extravascular hemolysis with paroxysmal nocturnal hemoglobinuria.

10. **Vafseo**: Approved on March 27, 2024, Vafseo contains vadadustat and is used for the treatment of anemia due to chronic kidney disease.

11. **Winrevair**: On March 26, 2024, Winrevair, with the active ingredient sotatercept-csrk, was approved for the treatment of pulmonary arterial hypertension.

12. **Duvyzat**: Duvyzat, containing givinostat, was approved on March 21, 2024. It is indicated for the treatment of Duchenne muscular dystrophy in individuals aged 6 years and older.

13. **Tryvio**: Approved on March 19, 2024, Tryvio contains aprocitentan and is used for the treatment of hypertension.

14. **Rezdiffra**: On March 14, 2024, Rezdiffra was approved. This drug, with the active ingredient resmetirom, is used for treating noncirrhotic non-alcoholic steatohepatitis with moderate to advanced liver scarring.

15. **Tevimbra**: Approved on March 13, 2024, Tevimbra contains tislelizumab-jsgr and is indicated for the treatment of unresectable or metastatic esophageal squamous cell carcinoma.

16. **Letybo**: Letybo, with the active ingredient letibotulinumtoxinA-wlbg, was approved on February 29, 2024. It is used to temporarily improve the appearance of moderate-to-severe glabellar lines.

17. **Exblifep**: Approved on February 22, 2024, Exblifep contains cefepime and enmetazobactam and is used for treating complicated urinary tract infections.

18. **Zelsuvmi**: On January 5, 2024, Zelsuvmi, containing the active ingredient berdazimer, was approved for the treatment of molluscum contagiosum.

## Novel Drug Approvals for 2023

1. **Izervay**: Approved on August 4, 2023, Izervay, which contains avacincaptad pegol, is indicated for the treatment of geographic atrophy secondary to age-related macular degeneration.

2. **Brenzavvy**: On January 20, 2023, Brenzavvy, with the active ingredient bexagliflozin, was approved to improve glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise.

3. **Bimzelx**: Approved on October 17, 2023, Bimzelx, containing bimekizumab, is used to treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

4. **Filsuvez**: Filsuvez, with the active ingredient birch triterpenes, was approved on December 18, 2023, for the treatment of wounds associated with dystrophic and junctional epidermolysis bullosa.

5. **Truqap**: Approved on November 16, 2023, Truqap, containing capivasertib, is indicated for the treatment of breast cancer that meets certain disease criteria.

6. **Pombiliti**: Pombiliti, with the active ingredient cipaglucosidase alfa-atga, was approved on September 28, 2023, to treat late-onset Pompe disease.

7. **Jesduvroq**: On February 1, 2023, Jesduvroq, containing daprodustat, was approved for the treatment of anemia caused by chronic kidney disease for adults on dialysis for at least four months.

8. **Ryzneuta**: Approved on November 16, 2023, Ryzneuta, with the active ingredient efbemalenograstim alfa-vuxw, is used for treating neutropenia.

9. **Orserdu**: Orserdu, containing elacestrant, was approved on January 27, 2023, for the treatment of estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.

10. **Elrexfio**: Approved on August 14, 2023, Elrexfio, which contains elranatamab-bcmm, is used for treating adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy.

11. **Epkinly**: On May 19, 2023, Epkinly, with the active ingredient epcoritamab-bysp, was approved for the treatment of relapsed or refractory diffuse large B-cell lymphoma (not otherwise specified) and high-grade B-cell lymphoma after two or more lines of systemic therapy.

12. **Wainua**: Approved on December 21, 2023, Wainua, containing eplontersen, is indicated for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis.

13. **Velsipity**: Velsipity, with the active ingredient etrasimod, was approved on October 12, 2023, for the treatment of moderately to severely active ulcerative colitis in adults.

14. **Veozah**: Approved on May 12, 2023, Veozah, containing fezolinetant, is used for the treatment of moderate to severe hot flashes caused by menopause.

15. **Posluma**: On May 25, 2023, Posluma, with the active ingredient flotufolastat F 18, was approved for use with positron emission tomography imaging in certain patients with prostate cancer.

16. **Fruzaqla**: Fruzaqla, containing fruquintinib, was approved on November 8, 2023, for the treatment of refractory, metastatic colorectal cancer.

17. **Exxua**: Approved on September 22, 2023, Exxua, with the active ingredient gepirone, is indicated for the treatment of major depressive disorder.

18. **Columvi**: Columvi, containing glofitamab-gxbm, was approved on June 15, 2023, for the treatment of diffuse large B-cell lymphoma, not otherwise specified, or large B-cell lymphoma arising from follicular lymphoma after two or more lines of systemic therapy.

19. **Fabhalta**: On December 5, 2023, Fabhalta, with the active ingredient iptacopan, was approved for the treatment of paroxysmal nocturnal hemoglobinuria.

20. **Leqembi**: Approved on January 6, 2023, Leqembi, containing lecanemab-irmb, is indicated for the treatment of Alzheimer’s disease.

21. **Joenja**: Joenja, with the active ingredient leniolisib, was approved on March 24, 2023, for the treatment of activated phosphoinositide 3-kinase delta syndromes.

22. **Xdemvy**: Approved on July 25, 2023, Xdemvy, containing lotilaner, is used for the treatment of Demodex blepharitis.

23. **Omvoh**: Omvoh, with the active ingredient mirikizumab-mrkz, was approved on October 26, 2023, for the treatment of ulcerative colitis.

24. **Ojjaara**: Approved on September 15, 2023, Ojjaara, containing momelotinib, is used for the treatment of intermediate or high-risk myelofibrosis in adults with anemia.

25. **Aphexda**: On September 8, 2023, Aphexda, with the active ingredient motixafortide, was approved for use with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma.

26. **Rivfloza**: Rivfloza, containing nedosiran, was approved on September 29, 2023, to lower urinary oxalate levels in patients 9 years and older with primary hyperoxaluria type 1 and relatively preserved kidney function.

27. **Paxlovid**: Approved on May 25, 2023, Paxlovid, with the active ingredients nirmatrelvir and ritonavir, is used for the treatment of mild-to-moderate COVID-19 in adults at high risk for progression to severe COVID-19.

28. **Ogsiveo**: On November 27, 2023, Ogsiveo, with the active ingredient nirogacestat, was approved for the treatment of adults with progressing desmoid tumors who require systemic treatment.

29. **Beyfortus**: Approved on July 17, 2023, Beyfortus, containing nirsevimab-alip, is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease.

30. **Skyclarys**: Skyclarys, with the active ingredient omaveloxolone, was approved on February 28, 2023, for the treatment of Friedrich’s ataxias.

31. **Sohonos**: Approved on August 16, 2023, Sohonos, containing palovarotene, is used to reduce the volume of new heterotopic ossification in adults and pediatric patients (aged 8 years and older for females and 10 years and older for males) with fibrodysplasia ossificans progressiva.

32. **Elfabrio**: Elfabrio, with the active ingredient pegunigalsidase alfa-iwxj, was approved on May 9, 2023, for the treatment of confirmed Fabry disease.

33. **Miebo**: Approved on May 18, 2023, Miebo, containing perfluorhexyloctane, is indicated for the treatment of signs and symptoms of dry eye disease.

34. **Jaypirca**: Jaypirca, with the active ingredient pirtobrutinib, was approved on January 27, 2023, for the treatment of relapsed or refractory mantle cell lymphoma in adults who have had at least two lines of systemic therapy, including a BTK inhibitor.

35. **Veopoz**: Approved on August 18, 2023, Veopoz, containing pozelimab-bbfg, is indicated for the treatment of patients 1 year old and older with CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease.

36. **Vanflyta**: Vanflyta, with the active ingredient quizartinib, was approved on July 20, 2023, for use as part of a treatment regimen for newly diagnosed acute myeloid leukemia that meets certain criteria.

37. **Augtyro**: Approved on November 15, 2023, Augtyro, containing repotrectinib, is used for the treatment of ROS1-positive non-small cell lung cancer.

38. **Zynyz**: Zynyz, with the active ingredient retifanlimab-dlwr, was approved on March 22, 2023, for the treatment of metastatic or recurrent locally advanced Merkel cell carcinoma.

39. **Rezzayo**: Approved on March 22, 2023, Rezzayo, containing rezafungin, is indicated for the treatment of candidemia and invasive candidiasis.

40. **Litfulo**: Litfulo, with the active ingredient ritlecitin

ib, was approved on June 23, 2023, for the treatment of severely patchy hair loss.

41. **Rystiggo**: Approved on June 26, 2023, Rystiggo, containing rozanolixizumab-noli, is used for the treatment of generalized myasthenia gravis in adults who are anti-acetylcholine receptor- or anti-muscle-specific tyrosine kinase antibody-positive.

42. **Ngenla**: Ngenla, with the active ingredient somatrogon-ghla, was approved on June 27, 2023, for the treatment of growth failure due to inadequate secretion of endogenous growth hormone.

43. **Inpefa**: Approved on May 26, 2023, Inpefa, containing sotagliflozin, is indicated for the treatment of heart failure.

44. **Filspari**: Filspari, with the active ingredient sparsentan, was approved on February 17, 2023, to reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progression.

45. **Xacduro**: Approved on May 23, 2023, Xacduro, containing sulbactam and durlobactam, is indicated for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex.

46. **Talvey**: Talvey, with the active ingredient talquetamab-tgvs, was approved on August 9, 2023, for the treatment of adults with relapsed or refractory multiple myeloma who have received at least four prior therapies.

47. **Defencath**: Approved on November 15, 2023, Defencath, containing taurolidine and heparin, is used to reduce the incidence of catheter-related bloodstream infections in adults with kidney failure receiving chronic hemodialysis through a central venous catheter.

48. **Qalsody**: Qalsody, with the active ingredient tofersen, was approved on April 25, 2023, for the treatment of amyotrophic lateral sclerosis in adults who have a SOD1 gene mutation.

49. **Loqtorzi**: Approved on October 27, 2023, Loqtorzi, containing toripalimab-tpzi, is used for the treatment of recurrent or metastatic nasopharyngeal carcinoma when used together with or following other therapies.

50. **Daybue**: Daybue, with the active ingredient trofinetide, was approved on March 10, 2023, for the treatment of Rett syndrome.

51. **Agamree**: Approved on October 26, 2023, Agamree, containing vamorolone, is indicated for the treatment of Duchenne muscular dystrophy.

52. **Lamzede**: Lamzede, with the active ingredient velmanase alfa-tycv, was approved on February 16, 2023, for the treatment of non-central nervous system manifestations of alpha-mannosidosis.

53. **Zavzpret**: Approved on March 9, 2023, Zavzpret, containing zavegepant, is indicated for the treatment of migraine.

54. **Zilbrysq**: Zilbrysq, with the active ingredient zilucoplan, was approved on October 17, 2023, for the treatment of generalized myasthenia gravis in adults who are anti-acetylcholine receptor (AChR) antibody positive.

55. **Zurzuvae**: Approved on August 4, 2023, Zurzuvae, containing zuranolone, is used for the treatment of postpartum depression.
